ClariVein

What ClariVein does

ClariVein is a product line of Merit Medical Systems, Inc. (NASDAQ: MMSI) that develops and markets a specialty infusion catheter system for the minimally invasive treatment of varicose veins and superficial venous reflux (chronic venous insufficiency). The technology was originally designed and developed by Vascular Insights, LLC, founded in 2005 in Quincy, Massachusetts by Michael Tal, MD, MBA and John Marano, PhD. The core innovation is Mechanical Occlusion Chemically Assisted (MOCA) endovenous ablation: a low-profile catheter (<3 French) with a rotating wire tip driven by a disposable Motor Drive Unit (MDU) at variable speeds between 2,000 and 3,500 RPM, which mechanically disrupts the vein endothelium while simultaneously infusing physician-specified sclerosant agents in a controlled 360-degree dispersion pattern. The system is fully disposable, requires no capital equipment purchase, and enables a non-thermal, tumescentless procedure that eliminates the multiple injections associated with thermal ablation modalities.

The product line is sold in two regulatory variants: ClariVein IC for the United States (intended for the infusion of physician-specified agents in the peripheral vasculature) and ClariVein OC for markets outside the United States (indicated for occlusion of incompetent veins in patients with superficial venous reflux). Distribution is hybrid: direct sales representatives and ordering through Vascular Insights in the US, paired with a network of country-specific distributors serving 35+ countries across North America, Europe, Asia, Oceania, Africa, and South America. The company targets vascular surgeons, interventional radiologists, ambulatory surgery centers, and office-based practices performing outpatient peripheral vascular procedures. End customers are patients with varicose veins and venous reflux disease seeking minimally invasive treatment with reduced postoperative pain, faster recovery, and office-based convenience.

ClariVein monetizes exclusively through per-procedure hardware sales of fully disposable catheters and the single-use Motor Drive Unit; no capital equipment or recurring software/service revenue is associated with the product. The technology is protected by multiple granted US patents (7,862,575; 7,967,834; 8,465,508; 8,686,645) and various issued foreign patents, with additional patents pending. Clinical evidence supporting the device includes 15+ peer-reviewed publications, 130,000+ cumulative units in market globally, and notable outcomes such as a 74% reduction in postoperative pain compared to radiofrequency ablation, a 96% closure rate at two years, and a median 1.0 day return to normal activities. In December 2018, Merit Medical Systems acquired the assets of Vascular Insights, and ClariVein is now marketed as "ClariVein powered by Merit Medical," leveraging the parent's global commercial infrastructure for continued distribution and clinical education.

Name

ClariVein

Legal name

Merit Medical Systems, Inc.

Website

https://clarivein.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

ClariVein, a Merit Medical Systems product line, develops disposable specialty infusion catheters using MOCA technology for minimally invasive, non-thermal treatment of varicose veins and superficial venous reflux, sold to vascular surgeons, interventional radiologists, and office-based practices across 35+ countries.

Ownership category

akta.pro rank

Product category

Peripheral Vascular Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)

akta.pro secondary industry

Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)

Keywords

• Minimally invasive catheters
• Endovenous ablation devices
• Venous insufficiency treatment
• Peripheral vascular devices
• MOCA mechanochemical ablation

Headquarters

HQ city

South Jordan

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. ClariVein Catheter Sales: Sale of fully disposable specialty infusion catheters. The device is single-use and fully self-contained with no capital equipment purchase required from customers.
2. Motor Drive Unit (MDU): Single-use Motor Drive Unit included with each procedure, fully disposable post-procedure.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

ClariVein designs, develops, and sells single-use specialty infusion catheters (ClariVein IC for the United States and ClariVein OC for markets outside the United States) that use proprietary Mechanical Occlusion Chemically Assisted (MOCA) technology — combining a rotating wire tip with physician-specified sclerosant infusion — for the minimally invasive treatment of varicose veins and superficial venous reflux. Each device is fully disposable and includes a low-profile (<3 French) catheter assembly and a single-use Motor Drive Unit, requiring no capital equipment purchase.

Product overview

ClariVein, powered by Merit Medical, offers a portfolio of specialty infusion catheters for the minimally invasive treatment of peripheral vascular disease, specifically varicose veins and superficial venous reflux. The product line consists of two regional variants: ClariVein®IC for the United States market and ClariVein®OC for markets outside the United States. Both products share the same core technology platform—a specialty infusion catheter with a rotating wire tip that enables 360-degree dispersion of physician-specified agents (sclerosants) to targeted treatment areas. The system comprises two main components: the Catheter Assembly (a disposable, low-profile <3 French catheter with rotatable dispersion wire) and the Motor Drive Unit (MDU) that powers wire rotation at variable speeds. The ClariVein devices are fully disposable, require no capital equipment purchase, and can be efficiently used in office settings without tumescent anesthesia or thermal energy.

Differentiator

Problem solved

Functional benefit

Brands

• ClariVein IC: Specialty infusion catheter for the US market, intended for the infusion of physician-specified agents in the peripheral vasculature.
• ClariVein OC

Products and services

• ClariVein IC Specialty infusion catheter with a rotating wire tip for controlled 360-degree dispersion of physician-specified agents, intended for the infusion of physician-specified agents in the peripheral vasculature. Fully disposable and minimally invasive; used in the United States for the treatment of varicose veins and superficial venous reflux.
• ClariVein OC Specialty infusion catheter designed for the occlusion of incompetent veins in patients with superficial venous reflux, featuring a rotating wire tip for 360-degree controlled dispersion of physician-specified agents. Fully disposable and minimally invasive; available for markets outside the United States.

Quantifiable outcome

• 74% less postoperative pain compared to radiofrequency ablation (RFA) for first 14 days
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Merit Medical Systems, Inc.coreStrategic or Co-development Partner · 17 December 2018Merit Medical acquired the assets of Vascular Insights, LLC on December 17, 2018. ClariVein is now powered by Merit Medical. The acquisition brought ClariVein's MOCA technology under Merit Medical's portfolio for the treatment of peripheral vascular disease. Merit Medical provides global commercial infrastructure and resources for ClariVein worldwide distribution.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Others

• Inari Medical: Inari Medical specializes in venous thromboembolism treatment with the FlowTriever (PE) and ClotTriever (DVT) systems. While focused on thrombectomy rather than ablation, Inari operates in adjacent venous intervention space with overlapping physician customers.
• Penumbra: Penumbra's vascular intervention portfolio (including the Indigo system for thrombectomy) operates in the broader peripheral vascular space. While not a direct varicose vein ablation competitor, Penumbra is a relevant adjacent peer in the vascular intervention category where ClariVein operates.

Direct peers

• Medtronic: Medtronic's ClosureFAST radiofrequency ablation (RFA) catheter and VenaSeal cyanoacrylate closure system are leading endovenous ablation technologies for varicose veins. As ClariVein's primary thermal and adhesive competitor, Medtronic competes directly across the same physician specialties and patient indications.
• AngioDynamics: AngioDynamics' VenaCure EVLT system is a leading endovenous laser treatment catheter for varicose veins. The company competes directly with ClariVein in office-based vein treatment procedures serving vascular surgeons and interventional radiologists.
• Biolitec: Biolitec markets the ELVeS radial fiber for endovenous laser treatment of varicose veins. The company directly competes with ClariVein in endovenous ablation procedures, offering a thermal alternative to ClariVein's non-thermal MOCA approach.
• VVT Medical: VVT Medical developed Flebogrif, a mechanochemical ablation catheter for varicose vein treatment. VVT directly competes with ClariVein in the same MOCA-based endovenous ablation category, targeting overlapping physician specialties.
• Teleflex: Teleflex (which acquired Vascular Solutions) markets the VariLase endovenous laser ablation system for varicose veins. Teleflex competes directly with ClariVein in office-based endovenous ablation procedures across similar patient populations.

Broad incumbents

• Abbott: Abbott has a broad peripheral vascular and interventional portfolio spanning vascular imaging, closure devices, and intervention tools. While not a direct varicose vein ablation competitor, Abbott operates in the broader peripheral vascular space where ClariVein participates.
• Boston Scientific: Boston Scientific has a peripheral vascular intervention portfolio that includes Varithena (polidocanol microfoam sclerotherapy), acquired through BTG. As a large medical device incumbent, Boston Scientific competes broadly with ClariVein in the peripheral vascular and venous intervention space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ClariVeinRoI
• Facebookfacebook.com/VascularInsightsLLC

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ClariVein